Safety Patterns over Time with Ozanimod During an Open-label Extension Trial in Patients with Relapsing Multiple Sclerosis (P10-6.012) | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Real-world Experience With Ozanimod at Two Academic Multiple Sclerosis Centers With Expanded 24-month Data (P4-20.003)Original Research · 2026
2Updated Study Data for Ozanimod in Relapsing Multiple Sclerosis2024
3Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosisHuman Clinical Trial · 2026 · 5 citations
4Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials and an Open-label Extension Trial (P2-6.007)2024
5Safety and Efficacy of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: 1-year Analysis of the ENLIGHTEN Study (P10-6.014)2024
6Comprehensive Analysis of Ozanimod-Related Adverse Events Based on the FAERS DatabaseOriginal Research · 2026
7A real-world data analysis of Ozanimod in the FDA Adverse Event Reporting System (FAERS) database2025 · 3 citations
8Real-world experience of ozanimod in adults with multiple sclerosisOriginal Research · 2026 · 1 citations
9A Review of the Association Between Pulse Wave Velocity and Cerebral Small Vessel Disease (P1-4.009)Neurology · 2026
10Factors Associated With Rate of Multiple Sclerosis Onset in a Cohort With Prior Infectious Mononucleosis Identified in Administrative DataNeurology · 2026

More from Neurology

More from University of California, San Francisco